<DOC>
	<DOCNO>NCT01318941</DOCNO>
	<brief_summary>This study describe long-term safety effectiveness , treatment pattern , patient report quality life associate ranibizumab treatment routine clinical practice approve indication include local product label .</brief_summary>
	<brief_title>Observe Effectiveness Safety Ranibizumab Real Life Setting</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Papilledema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Adult patient , within age limit define local regulation local product label , previously treat , currently treat initiate treatment ranibizumab approve indication include local product label Willing able provide inform write consent personally legal proxy Simultaneous participation study include administration investigational drug procedure Systemic ocular treatment VEGF inhibitor ranibizumab 90 day prior enrollment Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Ophthalmology , age-related macular degeneration , Diabetic Macular Edema , Retinal Vein Occlusion , ranibizumab</keyword>
	<keyword>Ophthalmology</keyword>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>Retinal Vein Occlusion</keyword>
	<keyword>LUMINOUS</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>